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Warfarin is the most commonly used oral anticoagulant in sub-Saharan Africa. Dosing is challenging 
due to a narrow therapeutic index and high inter-individual variability in dose requirements. To 
evaluate the genetic factors affecting warfarin dosing in Black-Africans, we performed a meta-
analysis of 48 studies (2,336 patients). Significant predictors for CYP2C9 and stable dose included 
rs1799853 (CYP2C9*2), rs1057910 (CYP2C9*3), rs28371686 (CYP2C9*5), rs9332131 (CYP2C9*6), and 
rs28371685 (CYP2C9*11) reducing dose by 6.8, 12.5, 13.4, 8.1, and 5.3 mg/week respectively. 
VKORC1 variants rs9923231 (-1639G>A), rs9934438 (1173C>T), rs2359612 (2255C>T), rs8050894 
(1542G>C), and rs2884737 (497T>G) decreased dose by 18.1, 21.6, 17.3, 11.7, and 19.6 mg/week, 
respectively while rs7294 (3730G>A) increased dose by 6.9 mg/week. Finally, rs12777823 (CYP2C 
gene cluster) was associated with a dose reduction of 12.7 mg/week. Few studies were conducted in 
Africa, and patient numbers were small, highlighting the need for further work in Black Africans to 





Cardiovascular disease (CVD) is a major public health burden worldwide, sub-Saharan Africa (SSA) 
included. In 2016, approximately 1.2 million deaths (12.9% of all deaths) in SSA were attributed to 
CVD (1). Warfarin, an oral anticoagulant, is important for management of venous thromboembolism, 
valvular heart disease and prevention of stroke in patients with atrial fibrillation. Despite the advent 
of new oral anticoagulants, warfarin remains the anticoagulant of choice in SSA, and other low-
income and emerging countries, mainly because of its significantly lower cost. Treatment with 
warfarin is difficult due to its narrow therapeutic window, large inter-patient variability in dose 
requirements and INR monitoring requirements. In SSA, the problems are compounded by high HIV 
and TB prevalence, lack of clinical expertise and infrastructure, and lack of validated dosing 
algorithms. Poor anticoagulation can lead to thrombotic or bleeding events: warfarin is among the 
top four drugs leading to hospitalization from adverse reactions in South Africa (2). 
To improve accuracy of warfarin dosing, several dose-prediction algorithms based on both clinical 
and genetic factors have been developed (3). Studies in Caucasians have revealed that genetic 
polymorphisms in CYP2C9 (encodes a warfarin-metabolizing enzyme) and VKORC1 (encodes 
warfarin’s molecular target) together with age, height, weight and interacting drugs account for 
approximately 50% of the required individual daily dose variability (3). However, these algorithms 
have largely been developed in White patients, and may not be applicable to other populations, 
including Black-Africans (4). This was demonstrated by the Clarification of Optimal Anticoagulation 
through Genetics (COAG) trial, in which a genotype-guided dosing algorithm performed worse for 
African Americans when compared to a clinical algorithm (5). This has been partly explained by the 
different allele frequencies in CYP2C9 and VKORC1 across the ethnicities. For instance, whereas the 
VKORC1 rs9923231 allele alone explains approximately 20–25% of the variance in warfarin 
maintenance dose in Caucasian and Asian populations (respective allele frequencies 0.39 and 0.89), 
it only accounts for approximately 6% of dose variability in African populations (allele frequency 
0.05) (6, 7). Similarly, the CYP2C9 alleles CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) are more 
prevalent in Caucasians (respective allele frequencies of 0.12 and 0.07) when compared to Asians 
(<0.01 and 0.03) and Africans (both <0.01) (7). In Black-Africans, additional CYP2C9 alleles 
(CYP2C9*5, *6, *8, and *11) may be more important than CYP2C9*2 and CYP2C9*3 (4, 8).  
It is important that all relevant ethnicity-specific variants affecting warfarin dose requirements are 
identified, characterized and accounted for to improve effectiveness of algorithms and to ensure 
that health inequities are not worsened. Previous reviews evaluating genetic factors modulating 
warfarin response in Black-African patients have had several limitations including a lack of structured 
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search strategy and focus on a limited number of genetic factors. This systematic review and meta-
analysis has therefore critically evaluated the current evidence on Black-African specific genetic 
factors affecting warfarin dose requirements, and other outcomes representing warfarin response.  
 
METHODS 
Search strategy and selection criteria 
A predefined protocol (PROSPERO: CRD42018110485), based on the principles of the Cochrane 
Handbook for Systematic Reviews of Interventions (9) and the Human Genome Epidemiology 
Network (HuGENet) HuGE Review Handbook (10) was followed. This report adheres to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Table S1). On 30 
October 2018, the University of Liverpool’s DISCOVER platform was used to search >480 online 
databases. Studies were identified using medical subject headings (MeSH terms) and text words 
related to “African” AND “warfarin” AND “genetic factors” (Table S2).  To determine the 
completeness of the DISCOVER search, a separate search was conducted in the MEDLINE database 
(Table S2). 100% consistency was observed. Next, lists of references from the identified studies were 
examined to identify additional eligible articles. To identify unpublished trials, trial registries 
including ClinicalTrials.gov and the International Clinical Trials Registry Platform were searched. 
Experts in the field were also contacted to identify further eligible studies. Unless a translated text 
was available, studies reported in a non-English language were excluded. There was neither 
restriction by year of publication nor by publication status. 
Observational and interventional studies where at least 5% of recruited warfarin-treated patients 
were Black-Africans, and which investigated the effect of at least one genetic factor on warfarin dose 
requirements and/or treatment response were included. For randomized controlled trials, only data 
from patients in the genotyped arm(s) were considered. The primary outcome was stable 
maintenance dose, and co-primary outcomes were time to stable dose and bleeding events. 
Secondary outcomes were: International Normalized Ratio (INR) above range in week 1 of 
treatment, time to achieving therapeutic INR, proportion of time spent within therapeutic INR range, 
warfarin sensitivity (≤1.5mg/day on 3 successive clinic visits), and warfarin resistance (>10mg/day on 
3 successive clinic visits). However, there was no restriction of inclusion criteria to studies that only 
investigated one or more of these outcomes; rather, studies investigating any other outcomes of 
warfarin response were also included. 
Data Extraction and quality assessment 
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Two reviewers (IGA and RO) independently screened titles and abstracts of the retrieved 
bibliographic records for eligibility and assessed full texts of potentially eligible studies for inclusion. 
A data extraction tool was developed to extract relevant information related to study and patient 
characteristics, study quality, outcomes and results. If key information could not be extracted from 
the published report, the study’s authors were contacted, and the data requested. Studies using the 
same or overlapping datasets (identified with reference to geographic regions, authors and their 
affiliations and recruitment sites) were flagged as such by identifying them as being part of a cluster 
of studies, to ensure that effect estimates from the same dataset were not included in the same 
meta-analysis more than once. To assess the methodological quality of each included study, two 
reviewers (IGA and RO) used criteria previously developed to assess the methodological quality of 
pharmacogenetic studies (11)). Disagreements were resolved by consensus. 
Data synthesis and analysis 
Data synthesis 
If ≥2 studies were present, a pooled estimate of effect for each gene variant and outcome 
combination was obtained by undertaking a meta-analysis. Which genotype groups to compare was 
dependent on what comparisons had been made in the primary papers. For CYP2C9 and where only 
summary genotype data was provided, the three genotype groups (wild-type homozygote, 
heterozygote and mutant-type homozygote) for each variant were obtained using a strategy 
provided in Text S1. A genetic model-free approach (12) was used to calculate the pooled effect 
estimates, such that a particular  genetic model did not have to be assumed. The genetic model-free 
approach was implemented in Stata (version 14) (13) using code provided in Text S1. Where there 
were no variant-type homozygotes, standard meta-analyses using R (version 3.5.1) (14) (R meta 
package (15)) were performed. Pooled mean differences with 95% confidence intervals (CIs) were 
generated and forest plots prepared for each genetic variant-outcome combination analyzed, using 
R (version 3.5.1) (14). 
Heterogeneity measures 
The magnitude of inconsistency in the study results was assessed by visually examining forest plots 
and considering the I2 statistic (9). Arbitrarily chosen categories of heterogeneity were defined as 
follows: I2 <30 %, low; I2 30–70 %, moderate; and I2 >70 %, high.   
Selective reporting 




Where >10 studies were available, publication bias was assessed using the linear regression test of 
funnel plot asymmetry (implemented using the metabias function in the R meta package (15)). A p-
value <0.1 was considered to show publication bias. Where asymmetry was suggested by a visual 
assessment, we performed exploratory analyses to investigate and adjust it (trim and fill analysis) 
using the trimfill function (R metafor package (16)). 
Sensitivity and subgroup analyses 
Sensitivity analyses were performed to assess the impact of the analysis approach used (the genetic-
model free approach versus the commonly-used bivariate pairwise approach (12)) and the strategy 
used to infer summary data for each CYP2C9 genotype group (Text S1) on the pooled effect 
estimates while subgroup analyses were performed stratified by subpopulation (country used as 
proxy for ethnicity), to try and address moderate and high heterogeneity.  
Secondary meta-analyses 
One of the largest warfarin-related studies to date is the International Warfarin Pharmacogenetics 
Consortium (IWPC) study in which 21 research groups from 9 countries contributed individual 
patient data for a total of 5700 warfarin-treated patients (17). As IWPC was a secondary study, it did 
not fit our eligibility criteria for inclusion, but we felt it important to include data from IWPC where it 
had not been reported in any of the included papers. However, as it was not possible to identify 
which of the 21 datasets in IWPC corresponded to which included study report, the IWPC data was 
ignored from the primary meta-analyses but secondary meta-analyses in which eligible IWPC sites 
were included (while excluding all studies whose population came from a site that was part of IWPC 
to avoid duplication) were conducted.  It was not possible to assess the methodological quality of 
the IWPC datasets.   
Confidence in cumulative evidence 
The strength of the body of evidence and the quality and strength of recommendations was 
assessed according to the Venice interim criteria (18). 
 
RESULTS 
Study selection and characteristics 
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Figure 1 depicts the literature search and selection process. Over 150 SNPs across >18 genes and >25 
outcomes were investigated by 77 studies.  Table S3 provides details of the studies; studies including 
similar populations are clustered together. Most studies (n = 42, 55%) had a retrospective cohort 
design while others were prospective (n = 25, 33%), both retrospective and prospective (n = 4, 5%), 
randomized controlled trials (n = 4, 5%) and case-control studies (n = 2, 3%). The median number of 
Black-African patients in the included studies was 115 (IQR: 31-269). Variant-specific details and the 
associations investigated for each of the primary, secondary and other outcomes in the different 
studies are provided in Tables S4 (CYP2C9), S5 (VKORC1), S6 (CYP4F2), S7 (other genes) and S8 (other 
outcomes). 
Methodological quality and risk of bias 
Qualitative methods were used to assess the methodological rigor of included studies (11) (Table S9 
and Spreadsheet S1). Most did not report using genotype quality control procedures (n = 39, 51%) 
and had not reported whether genotyping personnel were blinded to outcome status (n = 56, 73%). 
The reporting of missing genotype data was low across studies, with none of the studies reporting 
missing data (n = 38, 49%) conducting checks for missingness at random. Only 15 (20%) studies 
undertook tests for cryptic population stratification, with 27 (35%) studies not reporting testing for 
Hardy-Weinberg equilibrium. Only 2 (2.6%) studies provided details and justification of the modes of 
inheritance utilised. There was also a large variability in outcome definitions. For instance, 40 
different ‘stable dose’ definitions were observed in 56 studies (Table S10). The definitions of time to 
stable dose (5 different definitions in 5 studies), bleeding events (16 in 17 studies), time to 
therapeutic INR (6 in 6 studies), warfarin sensitivity and resistance (1 in 1 study) in the included 
papers are shown in Table S11. Lastly, only 14 (18%) of the trials reported measuring adherence to 
treatment. Whilst many issues of concern were raised in terms of the methodological quality, no 
studies stood out in terms of being of particularly low quality overall, and therefore sensitivity 
analyses based on methodological rigor were not performed. 
Meta-analyses  
Forty-eight studies representing 2,336 patients were included in the primary meta-analyses. For the 
remaining studies, even after contacting authors, data was insufficient to allow their inclusion. 
Summary results for all included studies are provided in Table 1 and Figures 2-4 (stable dose), Figure 
S1 (time to stable dose) and Figure S2 (proportion of time in therapeutic range). Tables S4-S8 show 
which studies were excluded and why. Results, if available, for studies that could not be included in 




Regarding CYP2C9 and stable dose (Table 1, Figure 2), significant predictors included rs1799853 (*2), 
rs1057910 (*3), rs28371686 (*5), rs9332131 (*6), and rs28371685 (*11) with heterozygotes 
respectively requiring 6.75 (95% CI 4.59; 8.91), 12.51 (6.83; 18.18), 13.38 (10.07; 16.68), 8.10 (0.83; 
15.36) and 5.31 (0.43; 10.18) mg/week less warfarin compared to wild-type homozygotes. 
rs2256871 (CYP2C9*9) mutant-type homozygotes on the other hand required 17.15 (9.14; 15.16) 
mg/week more compared to wild-type homozygotes, although the strength of evidence for this 
association was considered weak (only 3 mutant-type homozygotes). Only the association between 
rs1799853 (CYP2C9*2) and stable dose met our pre-defined criteria for assessing publication bias 
(>10 included studies), and for this we did not find any evidence to support it (linear regression test 
of funnel plot asymmetry p-value = 0.85).  
The VKORC1 variants rs9923231 (-1639G>A), rs9934438 (1173C>T), rs2359612 (2255C>T), rs8050894 
(1542G>C), and rs2884737 (497T>G) also led to reductions in weekly dose requirements:  
homozygotes for the variant alleles required 18.13 (13.92; 22.33), 21.56 (17.20; 25.92), 17.30 (12.74; 
21.86), 11.66 (4.42; 18.91), and 19.61 (14.32; 24.90) mg/week less warfarin, respectively, when 
compared with wild-type homozygotes. By contrast, heterozygotes required 10.28 (7.31; 13.25), 
11.14 (7.53; 14.76), 6.40 (2.76; 10.05), 3.77 (0.05; 7.49), and 8.16 (3.46; 12.87) mg/week less, 
respectively, compared with wild-type homozygotes (Table 1, Figure 3).  Conversely, mutant-type 
homozygotes and heterozygotes for the rs7294 (3730G>A) variant required a modest warfarin 
weekly dose increment of 6.93 (3.48; 10.38) and 4.83 (1.11; 8.55) mg, respectively. Regarding 
publication bias, only the first genotype-contrast (wild-type homozygotes versus heterozygotes) for 
the rs9923231 (-1639G>A) allele met our pre-defined criteria (four studies had zero weight in the 
second genotype contrast) and for this, we found some evidence of publication bias (linear 
regression test of funnel plot asymmetry p-value = 0.05). The trim and fill random effects analysis 
method estimated that the number of missing studies was two and that these missing trials did not 
affect the statistical significance of the pooled effect estimate (Figure S3). 
For other gene regions (Table 1, Figure 4), only the mutant-type homozygotes and heterozygotes for 
the rs12777823 (CYP2C gene cluster) variant required weekly doses that were significantly different 
from those of the corresponding wild-type homozygotes (respectively 12.74 (7.91; 17.58) and 4.40 
(1.42; 7.38) mg less). 
The results of the secondary analyses including IWPC sites (coded site_1, site_2, site_5, site_11, 
site_14, site_16, site_17, site_19, site_20, site_21 and site_22 in the IWPC data and ethnicity 
datasets (19)) (Figure S4) were similar to those obtained during the primary analyses except for 
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CYP2C9*6, CYP2C9*11, VKORC1 2255C>T and VKORC1 1542G>C which were no longer statistically-
significant (estimates for heterozygotes versus wild-type homozygotes respectively being -0.45 (-
11.87; 10.96), -4.05 (-10.44; 2.35), -3.25 (-6.75; 0.25) and -3.11 (-6.31; 0.10) mg/week). On the other 
hand, CYP2C9*8 produced statistically significant estimates for heterozygotes versus wild-type 
homozygotes (-6.42 (-9.44; -3.31) mg/week) in the pairwise meta-analysis (Figure S5). Interestingly, 
the non-significant estimate for variant-type homozygotes versus wild-type homozygotes was in the 
opposite direction (6.41 (-2.22; 15.05) mg/week). Regarding the strategy used to infer summary data 
for each CYP2C9 genotype group and except for *11 which was no longer statistically-significant 
(heterozygotes versus wild-type homozygotes estimate -3.36 (-9.24; 2.53) mg/week), the results 
mirrored those of the primary meta-analyses (Figure S6 and Tables S15-S16).  
Finally, where it was possible to conduct country-specific analyses (≥2 studies included from same 
country), we carried out sub-group analyses based on country from which participants were 
recruited. The countries where studies were conducted included the USA (n = 40 studies), Brazil (n = 
5), South Africa (n = 2), and Sudan (n = 1) (Table S17). Population-specific analyses produced non-
significant estimates for only rs1057910 (CYP2C9*3) (Brazil-only studies, wild-type homozygotes 
versus heterozygotes estimate -6.27 (-14.26; 1.72) mg/week, I2 = 0%) which differed from the overall 
pooled estimates which were statistically significant. 
Bleeding events and other outcomes 
We could not conduct meta-analyses for this outcome because follow-up time differed across the 
three studies (28 days (5) versus 2 years (20) versus 5 years (21)). In the individual studies, the 
comparisons between genetic variants and bleeding events were not statistically significant (Tables 
S4-S7).  Other outcomes are shown in Figures S1-S2.   
 
DISCUSSION 
We have comprehensively evaluated the effect of genetic factors that determine warfarin stable 
dose requirements and other end-points in Black-African patients. We have largely focused on genes 
involved in warfarin’s pharmacokinetics (CYP2C9), and pharmacodynamics (VKORC1), all of which 
have been implicated in determining warfarin response in Whites.   
CYP2C9 is the main metabolizing enzyme for the more potent S-enantiomer. The most commonly 
studied polymorphisms, rs1799853 (CYP2C9*2) and rs1057910 (CYP2C9*3), produce protein 
isoforms with only about 12% and <5% of wild-type enzyme activity (22, 23). Interestingly, although 
these polymorphisms are less common in Black-Africans (7), the effect on the reduction in weekly 
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warfarin dose requirement (6.8 and 12.5mg, respectively), was similar to that observed in White 
patients (3.9 and 12.5 mg/week less) (24), indicating that these polymorphisms should not be 
excluded from dosing algorithms. 
Other CYP2C9 polymorphisms (rs28371686 (CYP2C9*5), rs9332131 (CYP2C9*6), and rs28371685 
(CYP2C9*11)) which are more prevalent in Black-Africans (7) led to reductions in warfarin weekly 
dose by 13.4, 8.1, and 5.3 mg respectively. These polymorphisms also lead to reduced (25), null (26), 
and reduced (27) catalytic function, respectively. CYP2C9*8 (rs7900194) heterozygotes also required 
decreased weekly warfarin dose (4.5mg) as predicted by the functional effects of the allele (28), but 
this did not reach statistical significance. This could be attributed to the mutant-type homozygotes 
(n = 7) who required higher warfarin doses as shown in the bivariate sensitivity analysis. CYP2C9*9 
(rs2256871), despite the fact that it results in a change from histidine to arginine at position 251, has 
minimal effect on protein function (8). Thus, the higher warfarin dose requirements (17.2 mg/week) 
for the 3 mutant-type heterozygotes should be interpreted with caution, given the small sample size.  
The VKORC1 variants rs9923231 (-1639G>A), rs9934438 (1173C>T), rs2359612 (2255C>T), rs8050894 
(1542G>C), and rs2884737 (497T>G)  also led to reductions in weekly dose requirements by up to 
18.1, 21.6, 17.3, 11.7, and 19.6 mg, respectively.  Some of these results are similar to those 
previously observed in White patients (24). For instance, homozygotes for the rs9923231 and 
rs9934438 variant alleles required 20.0 and 22.0 mg/week less warfarin respectively compared to 
wild-type homozygotes (comparable to 18.1 and 21.6 mg/week in Black-African patients). This is 
biologically plausible for rs9923231 (-1639G>A), which is part of an enhancer box (E-box) consensus 
sequence CANNTG that may function as a repressor binding site (29). The G>A polymorphism leads 
to reduced transcription and decreased warfarin requirements (29, 30). However, this mechanism is 
yet to be confirmed, a process complicated by the fact that this variant is in near perfect linkage 
disequilibrium (LD) with several other variants including the intronic rs9934438 (1173C>T) variant 
also investigated in this study. The functions of the intronic rs2359612 (2255C>T), rs8050894 
(1542G>C), and rs2884737 (497T>G) variants are also unknown. The 1000 genomes population 
frequencies of these VKORC1 variants (rs9923231, rs9934438, rs2359612, rs8050894 and rs2884737) 
are respectively 0.05, 0.05, 0.18, 0.26 and 0.01 in Black-Africans compared with 0.39, 0.39, 0.39, 0.40 
and 0.26 in individuals of European ancestry (7). Two (rs9923231, rs9934438) are in LD (r2 > 0.9) in 
the Black-Africans whereas four (rs9923231, rs9934438, rs8050894, rs2359612) are in LD in 
Europeans.         
The rs7294 (VKORC1 3730G>A) variant (population frequency 0.45 in Black-Africans, 0.37 in 
Europeans (7)) increased weekly warfarin requirements by up to 6.9 mg.  It is located in the 3’-
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untranslated region (3’ UTR), which can be targeted by microRNAs resulting in gene silencing either 
by translational repression or by mRNA degradation. For instance, miR-133a, which targets this 
region, has been previously implicated in VKORC1 regulation (31). Specifically, the G>A mutation 
decreases the binding capacity of miR-133a leading to decreased translational repression and more 
copies of VKORC1 mRNA which would lead to higher warfarin dose requirements as we observed.  
In addition, rs12777823 (CYP2C cluster) was also associated with stable dose. Although, its role is 
currently unknown, it is associated with warfarin clearance in Blacks (32). Despite being common in 
other populations (respective allelic frequencies of 0.15 and 0.31 in European and East Asian 1000 
genomes (7) populations), this effect is observed in Africans only (allelic frequency of 0.25), 
suggesting that it may be in linkage disequilibrium with an unknown causal variant (32). 
Even though CALU1 and NQO1 are thought to be involved in warfarin’s mechanism of action 
(respectively binding to the vitamin K epoxide reductase complex and potentially reducing the 
quinone form of vitamin K) (33), the missense variants that we included in the meta-analyses 
(respectively rs2290228 and rs1800566) were not significantly associated with stable dose 
requirements. However, the strength of evidence for these associations was considered weak given 
the small sample sizes (only two studies included for each meta-analysis). 
We did not conduct meta-analyses for bleeding events.  Although the individual studies did not show 
an effect of genetic factors on the risk of bleeding, this may merely reflect a lack of power. Indeed, 
Limdi et al. (20) found that rs1057910 (CYP2C9*3) increased the risk of bleeding (hazard ratio 1.85) 
when African American data was combined with European American data.  
Several limitations of this study should be acknowledged. First, despite our comprehensive search 
strategy, we could not undertake some meta-analyses because of inadequate reporting. This was 
confounded by a low response rate (30.3%, 10 of 33 authors) when we requested additional 
information. However, the information obtained from the 10 individual authors was extensive, 
representing 39 studies and 10 abstracts. Consequently, only 33 (35.1%) of 94 studies could not be 
included in the quantitative syntheses. Although no studies stood out in terms of being of 
particularly low quality overall, there were many methodological issues of concern including 
heterogeneity in study populations and outcomes. Most studies included African Americans and 
Brazilians who are of West African ancestry, and so generalization to other sub-Saharan African 
populations should be done with caution. Another issue that needs to be taken into account is the 
degree of admixture with European and Ameridian populations (34) in the Black populations studied 
so far, which was not evaluated in most of the individual studies.  Despite these concerns, the sub-
group analyses showed that most pooled estimates were not significantly affected by the sub-
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populations involved. Finally, we excluded studies that did not report ‘Black’ participants and we 
could have therefore missed important data. For instance, we excluded 9 Egyptian studies during 
full-text screening. Our decision to exclude Egyptians could be justified by a genome-wide 
association study that revealed that North African populations share more genomic ancestry with 
some Asian populations compared to those from sub-Saharan Africa (35).  
In conclusion, our systematic review provides a quantitative estimate of the effect of different 
genetic variants on warfarin weekly dose requirements in Black-African patients. By showing that 
some variants that are more prevalent in Black-Africans may be important determinants of warfarin 
weekly dose requirements, this review has further demonstrated the importance of population-
specific dosing algorithms. Moreover, the total number of Black patients studied (n = 2,336) is much 
lower compared to Whites (n > 5400 as of December 19, 2007 (36)) and many of the studies were 
conducted in the US and Brazil, where there is a significant degree of admixture. This further 
emphasizes the fact that the number of studies conducted in Africa is small, which is worrisome 
given that warfarin is the most commonly used anticoagulant on this continent. In response to the 
poor quality of anticoagulation in sub-Saharan Africa, we have recently embarked on a collaborative 
project in Uganda and South Africa (War-PATH: WARfarin anticoagulation in PATients in Sub-
SaHaran Africa; http://warpath.info/) with the main aim of identifying clinical and genetic factors 
determining warfarin dose variability and ultimately develop better clinical and genetic dosing 
algorithms to improve anticoagulation quality. 
 
STUDY HIGHLIGHTS 
What is the current knowledge on the topic? 
Warfarin dosing requirements vary due to clinical and genetic factors. 
What question did this study address? 
What are the genetic factors affecting warfarin dosing in Black-African patients? 
What does this study add to our knowledge? 
This paper provides a quantitative estimate of the effect of different genetic variants on weekly 
warfarin dose requirements in Black-African patients. 
How might this change clinical pharmacology or translational science? 
14 
 
Most of the work in genomics, including pharmacogenomics, has been undertaken in White patients.  
This paper therefore provides valuable insights into what has been done in Black-African patients, 
and where further work needs to be undertaken. Understanding important ethnicity-specific genetic 
factors and incorporating them in warfarin dosing algorithms should ultimately improve 
anticoagulation quality for an underrepresented patient group. 
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Figure 1. Evidence search and selection 
Figure 2. Forest plots for associations between CYP2C9 and stable warfarin dose. *CYP2C9 star allele, 
†standard meta-analysis (fixed effects assumed with low heterogeneity (I2 <30%), else random effects), ‡article as data 
source (otherwise author-provided). CI = confidence intervals; CYP2C9 = cytochrome P450 family 2 subfamily C member 9; 
MD = mean difference; SD = standard deviation. 
Figure 3. Forest plots for associations between VKORC1 and stable warfarin dose. ‡article as data 
source (otherwise author-provided), §Shrif study estimates flipped, first genotype contrast with high heterogeneity so 
requires cautious interpretation. CI = confidence intervals; MD = mean difference; SD = standard deviation; VKORC1 = 
vitamin K epoxide reductase complex subunit 1. 
Figure 4. Forest plots for associations between other genes and stable warfarin dose. *CYP4F2 and 
NQO1 star alleles, †standard meta-analysis (fixed effects assumed with low heterogeneity (I2 <30%), else random effects), 
‡article as data source (otherwise author-provided). CI = confidence intervals; CYP2C = cytochrome P450 family 2 subfamily 
C; CYP4F2 = cytochrome P450 family 4 subfamily F member 2; MD = mean difference; NQO1 = NAD(P)H quinone 
dehydrogenase 1; SD = standard deviation. 
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Genotype counts Pooled estimates (mean differences 
(95% CI), heterogeneity) 
Strength of 
evidence§ 
Gene rs ID† Common 
name 






WT / V vs WT / 
WT 
V / V vs WT / 
WT 
CYP2C9 rs1799853 *2 Missense 13 (5, 21, 37-
47) 
2193 2054 139 0 -6.75 (-8.91; -
4.59), I2 = 15% 
NA Moderate 
rs1057910 *3 Missense 9 (5, 21, 38, 
39, 42-44, 46, 
47) 
1754 1706 48 0 -12.51 (-18.18; -
6.83), I2 = 62% 
NA Moderate 
rs28371686 *5 Missense 6 (39-41, 43, 
46, 47)  
1297 1277 20 0 -13.38 (-16.68; -




3 (40, 43, 47) 1044 1027 17 0 -8.10 (-15.36; -
0.83), I2 = 0% 
NA Moderate 
rs7900194 *8 Missense 7 (39-41, 43, 
45, 46, 48)  
929 821 97 11 -4.54 (-126.77; 
117.70), I2 = 0% 
-0.01 (-0.05; 
0.04), I2 = 0% 
Moderate 
rs2256871  *9 Missense 2 (40, 48) 299 242 54 3 0.06 (-4.29; 
4.41), I2 = 0% 
17.15 (9.14; 
25.16), I2 = 0% 
Weak 
rs28371685 *11 Missense 7 (38, 40, 43, 
45-48) 
1509 1474 35 0 -5.31 (-10.18; -






12 (5, 21, 38, 
39, 41-47, 
49) 
2019 1601 389 29 -10.28 (-13.25; -
7.31), I2 = 23% 
-18.13 (-22.33; -
13.92), I2 = 64% 
Moderate 
rs9934438 1173C>T Intronic 5 (39, 40, 50-
52) 
713 506 177 30 -11.14 (-14.76; -
7.53), I2 = 0% 
-21.56 (-25.92; -
17.20), I2 = 0% 
Moderate 
rs7294 3730G>A 3’ UTR 4 (40, 48, 51, 
53) 
666 222 319 12
5 
4.83 (1.11; 8.55), 
I2 = 0% 
6.93 (3.48; 
10.38), I2 = 2% 
Moderate 
rs2359612 2255C>T Intronic 3 (40, 51, 53) 535 298 182 55 -6.40 (-10.05; -
2.76), I2 = 0% 
-17.30 (-21.86; -
12.74), I2 = 47% 
Moderate 
rs8050894 1542G>C Intronic 4 (40, 50, 51, 
53) 
663 313 284 66 -3.77  (-7.49; -
0.05), I2 = 30% 
-11.66 (-18.91; -
4.42), I2 = 60% 
Moderate 
rs2884737 497T>G Intronic 2 (40, 53) 282 185 77 20 -8.16  (-12.87; -
3.46), I2 = 0% 
-19.61 (-24.90; -
14.32), I2 = 0% 
Moderate¶ 
CYP4F2 rs2108622 *3 Missense 5 (21, 39, 47, 
54, 55) 
990 824 160 6 2.64 (-292.45; 
297.72), I2 = 0% 
2.46 (-32.97; 




rs12777823 - Intergenic 4 (43, 45, 47, 
56) 
970 556 344 70 -4.40 (-7.38; -
1.42), I2 = 23% 
-12.74 (-17.58; -
7.91), I2 = 34%; 
Moderate 
CALU1 rs2290228 11G>A Missense 2 (39, 47) 293 254 34 5 -1.53 (-22.47; 
25.53), I2 = 52% 
NA|| Weak 
NQO1 rs1800566  *2 Missense 2 (39, 55) 303 208 85 10 -0.18 (-7.22; 
6.87), I2 = 0% 
7.63 (-7.33; 
22.60), I2 = 0% 
Weak 
*CYP2C9 star allele. †Abbreviations: N, sample size; NA, not applicable; rs ID, reference SNP (single nucleotide polymorphism) 
identifier; UTR, untranslated region; V, variant-type allele; WT, wild-type allele. ‡For CYP2C9, except for *6 (no function) and *9 
(normal function), variants have decreased function (8). §Based on the Venice interim criteria (18). ||Genetic model-free 
approach could not run (‘missing values encountered’ error). One study (39) had one variant-type homozygote taking 
77mg/week whereas another (47) had 4 variant-type homozygotes taking 26.3 ±  17.5 mg/week. ¶Secondary analysis (n = 675) 
also considered. 
 
